Steqeyma
Authorised
This medicine is authorised for use in the European Union
ustekinumab
MedicineHumanAuthorised
Romanian is available via eTranslation, the European Commission's machine translation service.
Translate to Romanian | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Steqeyma is a medicine used to treat:
- moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children from the age of 6 years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine called psoralen, before being exposed to ultraviolet light;
- active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not improved enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs). Stelara may be used alone or combined with methotrexate (a DMARD);
- moderately to severely active Crohn’s disease (a disease-causing inflammation of the gut) in adults and children weighing at least 40 kg whose condition has not improved enough with other treatments for Crohn’s disease or who cannot receive such treatments;
- moderately to severely active ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) in adults whose condition has not improved enough with other treatments for ulcerative colitis or who cannot receive such treatments.
Steqeyma contains the active substance ustekinumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Steqeyma is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Steqeyma is Stelara. For more information on biosimilar medicines, see here.
Steqeyma can only be obtained with a prescription and should be given under the supervision of a doctor who has experience in diagnosing and treating the diseases that Steqeyma is used for.
In plaque psoriasis and psoriatic arthritis, Steqeyma is given as an injection under the skin. The first injection is followed by a further injection 4 weeks later, and then by one injection every 12 weeks.
In Crohn’s disease and ulcerative colitis, treatment is started with Steqeyma infusion (drip) into a vein over at least 1 hour. Eight weeks after the infusion, Steqeyma is given as an injection under the skin. Patients then continue with Steqeyma injected under the skin every 8 or 12 weeks, depending on how well the treatment is working.
Patients or their caregivers may inject Steqeyma under the skin once they have been trained, if their doctor thinks that this is appropriate.
For more information about using Steqeyma, see the package leaflet or contact your doctor or pharmacist.
The active substance in Steqeyma, ustekinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target in the body. Ustekinumab attaches to two messenger molecules of the immune system called interleukin 12 and interleukin 23. Both are involved in inflammation and other processes that play an important role in psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. By blocking their activity, ustekinumab reduces the activity of the immune system and the symptoms of the disease.
Laboratory studies comparing Steqeyma with Stelara have shown that the active substance in Steqeyma is highly similar to that in Stelara in terms of structure, purity and biological activity. Studies have also shown that giving Steqeyma produces similar levels of the active substance in the body to giving Stelara.
In addition, a study of 509 patients with moderate to severe plaque psoriasis showed that Steqeyma was as effective as Stelara in improving symptoms. The improvement in symptom scores after 12 weeks was similar with both medicines.
Because Steqeyma is a biosimilar medicine, the studies on effectiveness of ustekinumab carried out with Stelara do not all need to be repeated for Steqeyma.
Studies carried out with Steqeyma are described in more detail in the medicine’s assessment reports.
For the full list of side effects and restrictions with Steqeyma, see the package leaflet.
The safety of Steqeyma has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Stelara.
The most common side effects with ustekinumab (which may affect up to 1 in 10 people) include headache and nasopharyngitis (inflammation of the nose and throat). The most serious side effect with ustekinumab (which may affect up to 1 in 1,000 people) is serious hypersensitivity reaction (allergic reaction) including anaphylaxis (sudden, severe allergic reaction with breathing difficulty, swelling, light-headedness, fast heartbeat, sweating and loss of consciousness).
Steqeyma must not be used in patients who have an active infection that the doctor considers important.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Steqeyma has a highly similar structure, purity and biological activity to Stelara and is distributed in the body in the same way. In addition, a study in plaque psoriasis has shown that Steqeyma and Stelara are equivalent in terms of safety and effectiveness in this condition.
All these data were considered sufficient to conclude that Steqeyma will have the same effects as Stelara in its authorised uses. Therefore, the Agency’s view was that, as for Stelara, the benefits of Steqeyma outweigh the identified risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Steqeyma have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Steqeyma are continuously monitored. Suspected side effects reported with Steqeyma are carefully evaluated and any necessary action taken to protect patients.
Steqeyma received a marketing authorisation valid throughout the EU on 22 August 2024.
Product information
Latest procedure affecting product information:VR/0000362091
14/09/2026
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Steqeyma
- Active substance
- ustekinumab
- International non-proprietary name (INN) or common name
- ustekinumab
- Therapeutic area (MeSH)
- Psoriasis
- Arthritis, Psoriatic
- Crohn Disease
- Anatomical therapeutic chemical (ATC) code
- L04AC05
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Plaque psoriasis
Steqeyma is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A).
Paediatric plaque psoriasis
Steqeyma is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
Psoriatic arthritis (PsA)
Steqeyma alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Adult Crohn’s Disease
Steqeyma is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.
Paediatric Crohn's Disease
Steqeyma is indicated for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy.
Ulcerative colitis
Steqeyma is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic.
Assessment history
News on Steqeyma
This page was last updated on